Bioequivalence Study (Candesartan 16 mg and Amlodipine 10 mg)

Inclusion Criteria: * Healthy male volunteer in the age between 19 and 55 years old. * Body mass index (BMI) in the range of 18.5 to 27.0 kg/m2 * Understand the requirements of the study and voluntarily consent to participate in the study. Exclusion Criteria: * Previous history or present of clinically significant digestive , cardiovascular, respiratory, psychiatric, endocrine, hepatobiliary, renal disease. * History of gastrointestinal disease or gastrointestinal surgery to affect drug absorption. * Subjects with a hereditary problems, for example, galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. * Subjects whose clinical laboratory test values are outside the accepted normal range. Especially, ASTor ALT \>1.5 times of the Upper Normal Limit or total bilirubin \> 1.5 times of the Upper Normal Limit * Positive test results for Hepatitis B antibodies, Hepatitis C virus antibody, and Syphilis regain test * Participation in any clinical investigation within 3 months prior to study drug administration * Subjects with whole blood donation within 60 days or component blood donation within 30days or blood transfusion within 30days prior to the first dosing. * SBP ≥ 140 mmHg or\< 115 mmHg, DBP ≥ 90 mmHg or \< 70 mmHg * Caffeine \> 400mg/day * Alcohol \> 30g/day * Cigarette \> 10 cigarettes/day. * Subjects who are judged unsuitable by investigators